

**Prometheus**  
Biosciences

**\$500 Million**  
Follow-On Offering

**svb** Securities  
Joint Bookrunner  
December 2022

## SVB Securities Serves as Joint Bookrunner for Prometheus Biosciences' (Nasdaq: RXDX) \$500 Million Follow-On Offering

### Key Transaction Highlights

- Publicly marketed transaction that launched December 7th post-close and priced December 8th post-close
- The offering followed Prometheus' December 7th announcement of positive topline data from the Company's ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies investigating PRA023 for the treatment of ulcerative colitis and Crohn's disease, respectively, leading to a 1-day stock price reaction of 165.7%.
- The stock traded up 22.3% during the marketing period and the base deal was upsized from \$250 million to \$500 million.
- Well oversubscribed from both new and existing investors
- Deal consisted of 4,545,455 shares of common stock offered at a public offering price of \$110.00 per share, representing a 14.8% premium to the price at launch and a 6.2% discount to last sale.
- Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments to fund the development of PRA023, PRA052 and its other research and development programs, and for working capital and general corporate purposes.
- This is SVB Securities' 2nd bookrunning offering for Prometheus and 49th bookrun equity offering in 2022.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**

53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**

227 West Trade Street  
Suite 2050  
Charlotte, NC 28202

**NASHVILLE**

40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**

1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**

255 California Street  
12th Floor  
San Francisco, CA 94111